This $602,361 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Yale University aims to develop deep learning-based models to personalize dosimetry and treatment planning for prostate cancer patients undergoing PSMA-targeted radiopharmaceutical therapy (RPT). The research will leverage imaging data from pre-treatment PSMA-PET scans and post-treatment PSMA-SPECT scans to build predictive models that can estimate radiation dosimetry and optimize individualized treatment regimens. This research project is scheduled to run from January 1, 2025 through December 31, 2029. The goal is to address the current limitations of standardized RPT dosing by enabling personalized treatment planning based on each patient's pharmacokinetics and biodistribution.
Generated 2/25/25, 3:31 AM